San Francisco-based pharmaceuticals company, Jaguar Health, Inc., has established itself as a major player in the treatment of gastrointestinal distress, with a particular focus on chronic and debilitating diarrhea. As part of its drive to develop prescription medicines that treat both people and animals, the company operates through two separate segments: Human Health and Animal Health. One of its flagship products is Mytesi, which is utilized for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS who are undergoing antiretroviral therapy. Jaguar Health is also currently developing Crofelemer, which is currently in Phase 3 clinical trials for the prophylaxis of diarrhea in adult cancer patients, as well as targeting rare and orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders. Other drugs in Jaguar Health's portfolio include NP-300, a second-generation anti-secretory antidiarrheal drug, and Canalevia, an oral plant-based drug candidate designed to alleviate chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. Since being founded in 2013, Jaguar Health has developed an impressive track record for innovation and excellence within the fast-moving world of pharmaceuticals.